A rapidly evolving landscape: immune checkpoint inhibitors in pretreated metastatic endometrial cancer.

Sarah A CookNeesha C DhaniPrafull GhatageDeanna McLeodVanessa SamouëlianStephen A WelchAlon D Altman

Published in: Therapeutic advances in medical oncology (2023)

Pembrolizumab plus lenvatinib is indicated for patients with unselected pretreated metastatic endometrial cancer and pembrolizumab monotherapy is a preferred option for patients with MMRd/MSI-H tumors.

Keyphrases

endometrial cancer
squamous cell carcinoma
small cell lung cancer
advanced non small cell lung cancer
combination therapy
open label
randomized controlled trial
clinical trial
study protocol